Immediate release drug delivery systems: a current update

Main Article Content

Suman Saha

Abstract

Instead of tremendous advancements in drug delivery, the oral route remains the most preferred route for the administration of therapeutic agents because of the low cost of therapy and ease of administration that leads to high levels of patient concordance. Incorporating an existing medicine into Newer Drug Delivery System (NDDS) are gaining popularities. One such approach is to formulate Immediate Release Tablet, which dissolve or disintegrate rapidly in saliva without the need of water within few seconds due to action of superdisintegrant in the formulation or other novel manufacturing technique. The demand for orally disintegrating tablets has enormously increased during the last decade over the other oral dosage forms (such as tablets, capsules, dry syrups, chewing gums, chewable tablets etc.) particularly for geriatrics and pediatrics, travelers, dysphasics, psychotics and non-cooperative patients. Considering the advantages of Immediate Release Tablet and its growing demand, an attempt has been made through this article to give an overview of preparation and new methodologies for the Immediate Release Tablet followed currently and in past including some patient information.

Article Details

How to Cite
SAHA, Suman. Immediate release drug delivery systems: a current update. Journal of Applied Pharmaceutical Research, [S.l.], v. 6, n. 4, p. 01 - 09, dec. 2018. ISSN 2348-0335. Available at: <https://japtronline.com/index.php/JOAPR/article/view/163>. Date accessed: 15 oct. 2019. doi: https://doi.org/10.18231/2348-0335.2018.0011.
Section
Articles

References

[1] Kuchekar BS, Bhise SB, Arumugam V. “Design of fast dissolving tablets”, Indian Journal of Pharmaceutical Education, 35(4), 150-153, (2001).
[2] Lindgren S, Janzon L. Dysphagia: “Prevalence of swallowing complaints and clinical findings”, Medical Clinics of North America, 77, 3-5, (1993).
[3] Doheny K. “You really expect me to swallow those horse pills?” Am Druggist, 208, 34-35, (1994).
[4] Sinha VR. “Cyclodextrins as sustained release carriers”, Pharmaceutical Technology, 26(10), 36- 46, (1994).
[5] “Biopharmaceutics Classification System Guidance”
http://www.fda.gov/cder/OPS/BCS_guidance.htm.
[6] Virely P, Varwood R, “Zydis- a novel, fast dissolving dosage form”, Manuf. Chem., 56(3), 36-37, (1990).
[7] Jaccard TT, Leyder J. ‘Une Novelle Frome Galenique’, Le lyoc, An. Pharm. Fr., 43(2), 123-131, (1985).
[8] Kuchekar BS, Atul C, Mahajan HS. “Mouth dissolving technologies”, Pharmaceutical Technology, June, 93-100, (2003).
[9] Parakh SR, Gothoskar AV. “A review of mouth dissolving technologies”, Pharmaceutical Technology, Nov, 92-100(2003).
[10] Chang RK, Guo X, Bumside BA, Couch RA. “Fast dissolving tablets”, Pharmaceutical Technology, 24(6), 52-58, (2000).
[11] Sinha VR. “Cyclodextrins as sustained release carriers”, Pharmaceutical Technology, 26(10), 36- 46, (1994).
[12] Heinemmane H, Rothe W. “Preparation of porous tablets”, US Patent No 3,885,026 (1975).
[13] Knitsch KW, Hagen A, Munz E, Determann H. “Production of porous tablets”, US Patent No 4134943, (1979).
[14] Roser BJ, Blair J. “Rapidly soluble oral dosage forms, method of making same and composition thereof”, US Patent No 5762961 (1998).
[15] Koizumi KI, Watanabe Y, Morita K, Utoguchi N, Matsumoto M. “New method for preparing high porosity rapid saliva soluble compressed tablets using mannitol with camphor, A sublimed material”, International Journal of Pharmaceutics, 152, 127-131, (1997).
[16] Allen LV, Wang B. “Process for making a particulate support matrix for making a rapidly dissolving tablet”, US Patent No 5587180 (1996).
[17] Cherukuri SR, Myers GL, Battist GE, Fuisz RC. “Process for forming quickly dispersing comestible unit and product there from”, US Patent No 5587172 (1996).
[18] Shangraw R, Mitrevej A, Shah M. “A new era of tablet disintegrants”, Pharmaceutical Technology, 4(10), 49-57, (1980).
[19] Ringard J, Guyot-Harmann AM. ”Calculation of disintegrant critical concentration in order to optimize tablets disintegration”, Drug Dev. Ind. Pharm., 14(15-17), 2321-2339, (1988).
[20] Cousin G, Bruna E, Gendrof E. “Rapidly disintegratable multiparticulate tablet”, US Patent No 5464632 (1995).
[21] Wehling F. Schuehle S. Madamala N. “Pediatric effervescent dosage form” US Patent No 5223264 (1993).
[22] Wehling F. Schuehle S. “Base-coated acid particles and effervescent formulation incorporating same”, US Patent No 5503846 (1993).
[23] Gregory GKE, Peach JM, Du Mayna JD. “Articles for carrying chemicals”, US Patent No 4371516 (1983).
[24] Mizumoto T, Masuda Y, Fukui M. “Intrabucally dissolving Compressed moulding and production process there of”, US Patent No 5576014 (1996).
[25] “CIMA Labs”, Inc CIMA-Technologies (2001).
http://www.cimalabs.com/tech.htm.
[26] “Profile Resources at Business. com.”, Cima Labs – Profile (2001). http://www.business.com/directory/pharmaceuticals_and_biotechnology/drug_delivery_systems/cima_labs/
[27] ‘Yamanouchi Pharma Technologies’, Inc. WOWTAB (2001). http://www.ypharma.com/wowtab.shtml.
[28] Myers GL, Battist GE, Fuisz RC. (Fuisz technologies), “Process and apparatus for making rapidly dissolving dosage units and product there from”, PCT Patent No WO 95/34293-A1 (1995).
[29] Proulx SM and Melchiorre HA. “New dosage forms lead to confusion”, US Pharm., 26(2), 68-70, (2001).